Kary Krochko, APRN
Family · Orange, CTNPI 1295904225
Payments from drug & device makers
Across 400 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Scilex Pharmaceuticals Inc.$745
- USWM, LLC$741
- Collegium Pharmaceutical, Inc.$718
- AbbVie$472
- Indivior Inc.$367
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,66399%
- Education$301%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 117 | $1,079 |
| Scilex Pharmaceuticals Inc. | 52 | $745 |
| USWM, LLC | 40 | $741 |
| Collegium Pharmaceutical, Inc. | 65 | $718 |
| AbbVie(2 entities) | 28 | $472 |
| Indivior Inc. | 16 | $367 |
| Ardelyx, Inc. | 12 | $199 |
| Almatica Pharma LLC | 10 | $199 |
| Azurity Pharmaceuticals, Inc. | 12 | $198 |
| Teva Pharmaceuticals USA, Inc. | 8 | $170 |
| Hikma Pharmaceuticals USA | 8 | $151 |
| Biohaven Pharmaceuticals, Inc. | 5 | $122 |
| Redhill Biopharma Inc. | 5 | $111 |
| Arbor Pharmaceuticals, Inc. | 5 | $95 |
| Pfizer | 3 | $66 |
| Amgen | 4 | $56 |
| Vertex | 2 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Alkermes, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Averitas Pharma Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$5,692 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 305 | $289,877 |
| RelistorMethylnaltrexone Bromide | 81 | $195,629 |
| ZtlidoLidocaine | 87 | $69,016 |
| MovantikNaloxegol Oxalate | 115 | $46,449 |
| Buprenorphine | 179 | $43,653 |
| LinzessLinaclotide | 52 | $29,978 |
| Diclofenac Sodium | 153 | $18,005 |
| Xtampza ErOxycodone Myristate | 27 | $14,644 |
| Oxycodone Hcl | 819 | $13,643 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 71 | $11,651 |
| Lidocaine | 117 | $11,532 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 436 | $10,146 |
| Hysingla ErHydrocodone Bitartrate | 13 | $9,354 |
| Gabapentin ErGabapentin | 13 | $9,236 |
| HorizantGabapentin Enacarbil | 13 | $8,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $718 | $304,521332 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,079 | $195,62981 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $745 | $69,01687 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $151 | $56,400294 claims |
| Redhill Biopharma Inc.Movantik | $111 | $46,449115 claims |
| AbbVieLinzess | $472 | $29,97852 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $95 | $8,23013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.
Other family in Orange
- Nicole StrandOrange$18K
- Christina YoungOrange$10K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.